Digital karyotyping market seen reaching $2.09 billion by 2030

The digital karyotyping market reached $1.29 billion in 2025 and is projected to grow to $2.09 billion by 2030, driven by demand for precision oncology, prenatal screening and AI-based genomic interpretation. North America led the market in 2025, while Asia-Pacific is expected to grow fastest through 2030.

Why it matters: - Digital karyotyping is becoming more important as genetic disorders, cancer research and precision medicine expand. - The market’s growth signals rising demand for tools that can detect chromosomal changes with greater accuracy than older methods. - The trend could accelerate adoption in molecular diagnostics, clinical genomics and rare disease screening.

What happened: - The Business Research Company published a market report projecting the digital karyotyping market will reach $2.09 billion by 2030. - The market was valued at $1.29 billion in 2025. - The report forecasts the market will rise to $1.42 billion in 2026, implying 10.3% CAGR. - The report projects 10.1% CAGR from 2026 to 2030. - North America held the largest market share in 2025. - Asia-Pacific is expected to be the fastest-growing region during the forecast period. - The report covers Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, the Middle East and Africa. - A free sample of the report is available here. - The full report is available here.

The details: - Digital karyotyping is a genomic technique that detects DNA copy number variations and chromosomal alterations by counting short DNA sequence tags across the genome. - The method creates a sequence-based map that can identify amplifications, deletions and rearrangements. - The report links market growth to the rising use of genomic methods in cancer studies, advances in DNA sequencing, greater investment in genetic disorder research, broader adoption of digital genomic tools and expansion of molecular diagnostic labs. - It also points to rising demand for precision oncology, AI-powered genomic interpretation, prenatal and rare disease screening, clinical genomics services and high-throughput digital karyotyping platforms. - The report highlights trends in high-resolution copy number analysis, sequence-based chromosomal mapping, improved detection of genomic changes, advanced bioinformatics integration and broader use in cancer genomics. - Digital karyotyping is especially useful for cancer genomes and genetic disorders because it can quantify genomic regions beyond the reach of conventional methods. - The UK National Health Service reported in May 2024 that about 17,000 people live with sickle cell disease and about 250 new cases occur annually.

Between the lines: - The report’s growth forecast reflects a broader shift toward more detailed, software-driven genomic analysis. - AI integration and bioinformatics support are likely becoming differentiators as labs look for faster interpretation of complex genetic data. - Stronger growth in Asia-Pacific may reflect expanding healthcare infrastructure and rising use of genomic diagnostics across the region.

What's next: - Market expansion is likely to continue as precision oncology and rare disease screening become more common in clinical settings. - Further adoption may depend on the rollout of higher-throughput platforms and improved genomic interpretation tools. - The report’s 2026 edition includes added features such as market attractiveness scoring, TAM analysis, company scoring matrices, Excel-based forecasting dashboards and updated graphics and tables.

The bottom line: - Digital karyotyping is moving from a specialized genomic tool toward a broader diagnostic market with strong growth potential through 2030.